KRAS up-regulated PD-L1 through p-REK instead of the p-AKT pathway, and the PD-1 blocker or ERK inhibitor can rescue the antitumor function of T cells and reduce the survival rate of KRAS mutated non-small-cell lung cancer cells [80]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.